Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL149581 | 1.00 | MAOB (0.59) | MAOBMAPTRAB9ANPC1NFE2L2 | |
| SCHEMBL29900779 | 1.00 | MAOB (0.59) | MAOBMAPTRAB9ANPC1NFE2L2 | |
| SCHEMBL10438847 | 0.87 | ALDH1A1 (0.58) | MAOBMAPTRAB9ANPC1NFE2L2 | |
| SCHEMBL69522 | 0.87 | ALDH1A1 (0.58) | MAOBMAPTRAB9ANPC1NFE2L2 | |
| SCHEMBL14930494 | 0.86 | PTGS2 (0.54) | MAOBMAPTRAB9ANPC1NFE2L2 | |
| SCHEMBL11061667 | 0.85 | ALDH1A1 (0.56) | MAOBMAPTRAB9ANPC1NFE2L2 | |
| SCHEMBL27647189 | 0.83 | KDM4E (0.46) | MAOBMAPTRAB9ANPC1NFE2L2 | |
| SCHEMBL2149382 | 0.83 | KDM4E (0.46) | MAOBMAPTRAB9ANPC1NFE2L2 | |
| SCHEMBL30578183 | 0.83 | KDM4E (0.46) | MAOBMAPTRAB9ANPC1NFE2L2 | |
| SCHEMBL30814249 | 0.83 | MAOB (0.56) | MAOBMAPTRAB9ANPC1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115927221-B | Method for synthesizing methyl epoxycinnamate compound by biocatalysis | 湖南师范大学 | 2024-12-31 | — | — | CN | disclosed |
| US-11896593-B2 | Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2024-02-13 | — | — | US | disclosed |
| EP-4211125-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | Bio-Pharm Solutions Co., Ltd. (KR) | 2023-07-19 | — | — | EP | disclosed |
| CN-116234798-A | Sulfamate derivative compounds for the treatment or alleviation of psychotic disorders | 生物药品解决方案有限公司 | 2023-06-06 | — | — | CN | disclosed |
| CN-115927221-A | Method for synthesizing epoxy methyl cinnamate compounds through biocatalysis | 湖南师范大学 | 2023-04-07 | — | — | CN | disclosed |
| CN-115927221-A | Method for synthesizing epoxy methyl cinnamate compounds through biocatalysis | 湖南师范大学 | 2023-04-07 | — | — | CN | disclosed |
| CN-115427394-A | Heterocyclic compounds for modulating NR2F6 | TES制药有限责任公司 | 2022-12-02 | — | — | CN | disclosed |
| US-20220219155-A1 | Compositions And Methods For Visible-Light-Controlled Ruthenium-Catalyzed Olefin Metathesis | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2022-07-14 | — | — | US | disclosed |
| US-20220218702-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2022-07-14 | — | — | US | disclosed |
| US-20220218702-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2022-07-14 | — | — | US | disclosed |
| US-5834476-A | DERIVATIVE OF CAMPTOTHECIN, ANTITUMOR AGENT, ANTICARCINOGENIC AGENT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1998-11-10 | — | — | US | disclosed |
| US-5770605-A | Method for treating leukemia with a hexa-cyclic compound | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1998-06-23 | — | — | US | disclosed |
| US-5658920-A | ANTITUMOR AGENTS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1997-08-19 | — | — | US | disclosed |
| US-5637770-A | Hexa-cyclic compound | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1997-06-10 | — | — | US | disclosed |
| EP-0495432-B1 | Hexa-cyclic compound | DAIICHI SEIYAKU CO (JP) | 1996-05-29 | — | — | EP | disclosed |
| EP-0495432-A1 | Hexa-cyclic compound | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1992-07-22 | — | — | EP | disclosed |
| EP-0266725-A1 | 4-cyano-4-(fluorophenyl)-3-(substituted phenyl) butyric acids, esters and derivatives thereof, and a method of selectively controlling undesirable vegetation in rice therewith | AMERICAN CYANAMID COMPANY (US) | 1988-05-11 | — | — | EP | disclosed |
| US-4237306-A | ELECTROPHILIC REACTIONS WITH ALKYL ARYL KETONES TO PRODUCE METHYL ARYL ALKANOATES | EMERY INDUSTRIES, INC. (US) | 1980-12-02 | — | — | US | disclosed |
| US-4172955-A | REARRANGMENT OF A CINNAMALDEHYDE TO A PHENYLMALONDIALDEHYDE TETRAMETHYL DISACETAL | EMERY INDUSTRIES, INC. (US) | 1979-10-30 | — | — | US | disclosed |
| US-4067823-A | Thallium(III) reagents supported on montmorillonite clay minerals and oxythallation processes for utilizing same | EMERY INDUSTRIES, INC. (US) | 1978-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218702-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | SLC6A4, SLC6A3, SLC6A2 | MAOB 245/4885MAPT 573/4885RAB9A 3264/4885 |
| US-20220219155-A1 | Compositions And Methods For Visible-Light-Controlled Ruthenium-Catalyzed Olefin Metathesis | PPOX, CYBA, CYBB | MAOB 149/4885MAPT 1538/4885RAB9A 2203/4885 |
| US-11896593-B2 | Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder | SLC6A4, SLC6A3, SLC6A2 | MAOB 245/4885MAPT 573/4885RAB9A 3264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.